Dermatology (Basel, Switzerland) · 2008
Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, Viallette C, Revuz J
Аннотация
BACKGROUND: In analogy to acne, oral isotretinoin has been considered in the treatment of hidradenitis suppurativa (HS).
OBJECTIVES: To assess the efficacy of oral isotretinoin according to patients.
METHODS: From 1999 to 2006, 358 consecutive HS patients were interviewed and examined. A standardized record of the data was performed for each patient during the first consultation. Patients were questioned regarding the effect of previous treatment with oral isotretinoin: patients had to grade the effect as either 'improved', 'no effect' or 'worse'.
RESULTS: Fourteen patients (16.1%) declared an improvement, 67 patients (77%) no effect and 6 patients (6.9%) worsening of HS.
CONCLUSION: According to our patients, oral isotretinoin is not effective in the treatment of HS.
OBJECTIVES: To assess the efficacy of oral isotretinoin according to patients.
METHODS: From 1999 to 2006, 358 consecutive HS patients were interviewed and examined. A standardized record of the data was performed for each patient during the first consultation. Patients were questioned regarding the effect of previous treatment with oral isotretinoin: patients had to grade the effect as either 'improved', 'no effect' or 'worse'.
RESULTS: Fourteen patients (16.1%) declared an improvement, 67 patients (77%) no effect and 6 patients (6.9%) worsening of HS.
CONCLUSION: According to our patients, oral isotretinoin is not effective in the treatment of HS.